Old West Investment Management LLC Acquires 14,087 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Old West Investment Management LLC increased its holdings in Elanco Animal Health by 3.6%, acquiring an additional 14,087 shares, making its total ownership 407,869 shares valued at approximately $4.28 million.
• Elanco's stock price has seen positive movement, opening at $17.89, with a twelve-month range of $8.02 to $18.08, reflecting a market capitalization of $8.89 billion.
• The company recently reported earnings of $0.26 per share, surpassing analysts' expectations, with a revenue increase of 4.8% year-over-year, and it has set future earnings guidance for the third quarter and full fiscal year.

Old West Investment Management LLC increased its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 3.6% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 407,869 shares of the company's stock after buying an additional 14,087 shares during the quarter. Elanco Animal Health comprises approximately 1.5% of Old West Investment Management LLC's portfolio, making the stock its 23rd biggest position. Old West Investment Management LLC owned about 0.08% of Elanco Animal Health worth $4,283,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Allworth Financial LP increased its holdings in Elanco Animal Health by 791.7% in the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after buying an additional 2,090 shares in the last quarter. CoreCap Advisors LLC purchased a new position in Elanco Animal Health in the fourth quarter worth about $29,000. NBC Securities Inc. purchased a new position in Elanco Animal Health in the first quarter worth about $40,000. Parallel Advisors LLC boosted its position in Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after purchasing an additional 1,852 shares during the last quarter. Finally, Versant Capital Management Inc boosted its position in Elanco Animal Health by 65.9% in the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock worth $46,000 after purchasing an additional 1,740 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Stock Up 2.3%

ELAN stock opened at $17.8930 on Monday. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $18.08. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The stock has a market cap of $8.89 billion, a P/E ratio of 20.81, a PEG ratio of 3.32 and a beta of 1.66. The business's 50-day moving average price is $15.08 and its 200-day moving average price is $12.47.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.19 billion. During the same period in the previous year, the firm earned $0.30 EPS. The business's quarterly revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Zacks Research cut Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. Stifel Nicolaus raised their target price on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Leerink Partners raised Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price on the stock in a research report on Thursday, July 17th. Piper Sandler raised their target price on Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, August 11th. Finally, Leerink Partnrs raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $17.33.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.